key: cord-0842916-lo1jgnui
authors: Marini, Corrado P.; Lewis, Erin; Petrone, Patrizio; Zenilman, Ariela; Lu, Zhai; Rivera, Aksim; McNelis, John
title: The incidence and the impact of deep vein thrombosis on the outcome of patients with COVID-19 infection
date: 2021-11-11
journal: J Vasc Surg Venous Lymphat Disord
DOI: 10.1016/j.jvsv.2021.10.013
sha: da7d0039736702787632c363a1f0600eccc4e743
doc_id: 842916
cord_uid: lo1jgnui

BACKGROUND: Deep vein thrombosis (DVT) has been reported to occur at varying rates in patients with COVID-19. Limited data exist regarding comparison with non-Covid-19 patients with similar characteristics. The objective was to compare the rates of DVT in patients with and without COVID-19 and to determine the impact of DVT on outcome. METHODS: Retrospective, observational cohort study. Single institution, level 1 Trauma Center. COVID-19 patients compared with a group of non-COVID-19. Patients included a non-COVID-19 group from March 20, 2019 to June 30, 2019 and a COVID-19 group from the same interval in 2020. Standard prophylactic anticoagulation with heparin 5,000 units three times daily or enoxaparin 40 mg daily not weight adjusted (n=573) and enoxaparin 40 mg daily not weight adjusted (n=213). Two primary outcomes included the rate of DVT in the COVID-19 group compared to the historic control, and the impact of DVT on mortality. Subgroup analysis included patients with adult respiratory distress syndrome (ARDS), pulmonary embolism (PE), and intensive care unit patients (ICU). RESULTS: The rate of DVT and PE in the 573 patients, age 61 ± 17 years, male 44.9%, was 71/573 (12.4%) and 19/573 (3.3%) compared to 72/213 (33.8%) and 15.213 (7.0%) in COVID-19 patients, age 61 ± 16 years, male 61.0%. Unprovoked PE occurred in 10/15 (66.7%) in COVID-19 patients compared to 8/497 (1.6%) in non-COVID-19. Patients with ARDS (n=60) had an incidence of DVT 28/60 (46.7%) versus 44/153 (28.8%), p=0.01. ICU patients had an increased rate of DVT in COVID-19 patients: 39/90 (43.3%) versus 33/123 (33.3%), p=0.01. Risk factors for mortality included age, DVT, multiple organ failure syndrome, and prolonged ventilatory support with the following odd ratios: 1.030, 95% CI 1.002 – 1.058, 2.847, 95% CI 1.356-5.5979, 4.438, 95% CI 1.973-9.985, and 5.321, 95% CI 1.973-14.082. CONCLUSIONS: The incidence of DVT in COVID-19 patients receiving standard dose not weight-adjusted prophylactic anticoagulation is high, particularly in ICU patients. DVT is one of the contributing factors to increased mortality. These results suggest re-evaluation of the present standard dose thromboprophylaxis in patients with COVID-19.

As of this writing, SARS CoV 2 (COVID-19) has affected more than 31 million people and 2 caused more than 560,000 deaths in the US 1 accompanying the presence of fibrin thrombi within small vessels, are also been associated with 8 mortality 3,4 . While a multicenter retrospective study of 400 COVID-19 patients receiving 9 standard-dose prophylactic anticoagulation radiologically confirmed an incidence of venous 10 thromboembolism (VTE) of only 4.8%, a recent meta-analysis has documented an incidence of 11 deep vein thrombosis (DVT) and pulmonary embolism (PE) of 14.8% and 16.5%, respectively 5 . 12 Another systematic review reported an overall rate of VTE of 21%, with a rate of 5% in non- 13 intensive care unit (ICU) patients and 31% among ICU patients with the odds of mortality 14 increasing by as much as 74% with VTE 6 . Based on the varying rates of DVT reported by 15 studies, the association of elevated D-dimer levels with the increasing severity of the COVID-19 16 disease -and the extent to which DVT in COVID-19 may increase mortality -we designed this on the CT scan of the chest in patients with arterial oxygen saturation < 90% on room air with a 15 ratio of arterial partial pressure of oxygen to fraction of inspired oxygen < 300 while breathing at 16 to 15/213 (7.0%) (p=0.02). Of note, more patients in the COVID-19 group had unprovoked PE; 7 10/141 (7.0%) as opposed to 8/502 (1.6%) in the non-COVID-19 group (p=0.0006). Patients 8 with unprovoked PE were younger than those whose PE could be linked to DVT; 49 ± 11 as 9 opposed to 62 ± 10, respectively. However, other than age there was no other difference -10 including mortality -between the 10 unprovoked and five DVT-related PE patients (Table 2) .

There was no difference in the mortality of patients with and without PE, 3/15 (20.0%) as Table 2 ). The incidence of PE was 15/213 (7.0%) with 10 unprovoked were admitted to the ICU (Table 4 ). There was no difference in age and sex between the two 20 groups. The incidence of DVT of non-COVID-19 ICU patients was lower than for the ward 21 patients, 3/41 (7.3%) vs. 68/532 (12.8%). In contrast, the incidence of DVT was higher for the The rate of DVT in the COVID-19 group was 33.8%, despite conventional 16 pharmacologic prophylaxis, which is higher than the 14.5% reported by Baccellieri et al, and the 17 rate of 20% reported by Malas et al 6, 13 . The rate of DVT in the 90 critically ill ICU patients was 18 43.3%, which is also higher than the rate of 27% of VTE reported Klok et al 14 .

The relative rate of DVT was 63.3% higher compared to the rate of DVT in the cohort of 20 patients without COVID-19 admitted in 2019. While some of the increased rate can be attributed 21 to the weekly surveillance protocol implemented in the COVID-19 patients, the magnitude of the 22 difference cannot be ascribed solely to the intensity of surveillance. Of interest, while the rate of DVT in COVID-19 ICU patients was higher than non-ICU patients (43.3% vs. 26.8%, 1 respectively), we observed a low incidence of DVT in the non-COVID-19 ICU patients (7.3%, 2 opposed to 12.8% for patients on the ward). We believe that the lower rate of DVT in non- While there was a significant difference in the level of DD-CUS between survivors and non-18 survivors by univariate analysis, the significance was not retained after stepwise logistic 19 regression analysis. Therefore, we could not corroborate the negative impact of elevated D-dimer 20 on survival as it has been previously reported 12 .

The incidence of PE in the COVID-19 cohort was 7.0% consistent with the range of rates group was 1.6% (8/502 patients). Based on the high rate of DVT in our study, we believe that the 2 prevalence of DVT in the COVID-19 group was not underestimated. We, therefore, propose that 3 -at least in some cases -pulmonary thrombosis, rather than embolism, is the pulmonary 4 pathological entity associated with COVID-19. Other than a younger age for the patients with 5 unprovoked PE, we could not document any difference -including the level of D-dimer -that 6 could help identify risk factors for unprovoked PE. There was no difference in mortality between 7 patients with unprovoked and DVT-related PEs. All PEs in COVID-19 patients were non-fatal. 8 The mortality of 3/15 patients with PE was attributable to MOFS. In contrast to a reported higher 9 ICU mortality in patients with PE, the mortality of patients with PE was not higher than that 10 experienced by patients without PE, 20.0 vs 23.7%, respectively 22 .

The 28.2% rate of ARDS was lower that the reported rate (61% -81%) of patients Based on our results, we conclude that -despite conventional DVT prophylaxis -patients with 13 COVID-19 have a higher incidence of DVT and unprovoked PE compared to patients without it. 

Latest Map and Case Count -The New York Times

Population Risk Factors for COVID-19 Mortality in 21

The impact of 15 deep vein thrombosis in critically ill patients: a meta-analysis of major clinical outcomes

Efficacy 18 and safety of fondaparinux for the prevention of venous thromboembolism in older acute 19 medical patients: randomised placebo controlled trial